IVVD logo

INVIVYD INC

IVVDNASDAQ
🏆 #3460 by market capUS Equity
$967.33▼ $23.51 (−2.43%)
Simulated price
🔔
Track IVVD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$280M
Small Cap
📈Revenue Growth (YoY)
+26.3%
High Growth
📊Gross Margin
92.2%
High
💵FCF Margin
—
⚖️P/S Ratio
4.8x
Fair
Otter Score
56
Weak
No chart data available for IVVD.

Trading Snapshot

Day Range
$957.63 – $974.56
52-Week Range
$0.53 – $3.07
Volume
$2.76B
Avg Volume
$2.89B
Shares Outstanding
294.6M
Next Earnings
Nov 10, 2026

Fundamentals Snapshot

Annual Revenue
$53M
Last Q Revenue
$14M
P/E Ratio
—
P/S Ratio
4.8x
EPS (TTM)
$-0.37
Dividend Yield
—
Dilution (1yr)
+45.3%

Why Investors Own IVVD

  • ✓High-growth profile — revenue up +11.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 33% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IVVD logo

INVIVYD INC

IVVD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53M▲ +110.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.0%▼ −0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$56M▼ −68.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$58M▼ −65.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
172.2M▲ +45.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$224M▲ +$156M YoY
StockOtter · stockotter.space

About INVIVYD INC

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1,145.42
▲ +18.4% Upside
High Target$1,430.79
Low Target$1,007.71
Based on 21 analysts

Latest News & Updates

🚀
Barron’s·2h ago

INVIVYD INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift IVVD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

INVIVYD INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.